Irritable bowel syndrome cost-effectiveness of therapy

Jump to navigation Jump to search

Irritable bowel syndrome Microchapters


Patient Information


Historical Perspective




Differentiating Irritable bowel syndrome from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Criteria

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


X Ray




Other Imaging Findings

Other Diagnostic Studies


Medical Therapy



Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Case Studies

Case #1

Irritable bowel syndrome cost-effectiveness of therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Irritable bowel syndrome cost-effectiveness of therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Irritable bowel syndrome cost-effectiveness of therapy

CDC on Irritable bowel syndrome cost-effectiveness of therapy

Irritable bowel syndrome cost-effectiveness of therapy in the news

Blogs on Irritable bowel syndrome cost-effectiveness of therapy

Directions to Hospitals Treating Irritable bowel syndrome

Risk calculators and risk factors for Irritable bowel syndrome cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Cost-effectiveness of therapy

  • The aggregate cost of IBS in the United States has been estimated at $1.7-$10 billion in direct medical costs, with an additional $20 billion in indirect costs, for a total of $21.7-$30 billion.[1]
  • A 49% annual increase in medical costs is associated with a diagnosis of IBS.[2][3]
  • IBS patients have average annual direct costs of $5,049 and $406 in out-of-pocket expenses.[4]
  • IBS patients have a reported 34.6% loss in productivity, corresponding to 13.8 hours lost per 40 hour week.[5]
  • IBS patients have high costs for physician visits, outpatients visits, and prescription drugs.
  • In 2007, IBS was associated with an increase of $962 in Medicaid costs in California, and $2191 in North Carolina.
  • Cost of IBS is comparable to asthma patients.[6]

Research spending on IBS


  1. Hulisz D. (2004). "The burden of illness of irritable bowel syndrome: current challenges and hope for the future". J Manag Care Pharm. 10 (4): 299–309. PMID 15298528.
  2. Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD. (2001). "Costs of care for irritable bowel syndrome patients in a health maintenance organization". Am J Gastroenterol. 96 (11): 3122–9. PMID 11721759.
  3. Leong SA, Barghout V, Birnbaum HG; et al. (2003). "The economic consequences of irritable bowel syndrome: a US employer perspective". Arch. Intern. Med. 163 (8): 929–35. doi:10.1001/archinte.163.8.929. PMID 12719202.
  4. "Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain". Aliment Pharmacol Ther. 26 (2): 237–48. 2007. PMID 17593069. Text " author Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ, Whitehead WE. " ignored (help)
  5. Paré P, Gray J, Lam S; et al. (2006). "Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study". Clinical therapeutics. 28 (10): 1726–35, discussion 1710–1. doi:10.1016/j.clinthera.2006.10.010. PMID 17157129.
  6. Martin B, Ganguly R, Pannicker S, Feride F;Barghout V (2003). "Utilization Patterns and Net Direct Medical Costs Medicaid of Irritable Bowel Syndrome". Curr Med Res Opin. 19 (8): 771–780. PMID 12719202.

Template:WH Template:WS